Early prescription data for Eli Lilly and Co.'s (NYSE:LLY) newly launched obesity pill suggest a measured start compared to Novo Nordisk A/S' (NYSE:NVO) oral Wegovy, as investors track early traction in a rapidly evolving weight-loss drug market dominated by injectables.

Early Prescription Trends Show Slower Start For Lilly

Reuters, citing IQVIA data, reported that Eli Lilly recorded 1,390 prescriptions for its newly launched obesity pill in the U.S. for the week ended April 10.

In comparison, Novo Nordisk's oral Wegovy saw 3,071 prescriptions within just the first four days following its January 5 launch, indicating a stronger initial uptake.

The data highlights a slower early ramp for Lilly's pill, though the company had previously flagged potential variability in early prescription trends.